Salvage surgery in lung cancer following definitive therapies.
carcinoma
lung cancer
non-small-cell lung
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
10
11
2022
received:
29
10
2022
accepted:
11
11
2022
entrez:
11
1
2023
pubmed:
12
1
2023
medline:
14
1
2023
Statut:
ppublish
Résumé
Salvage surgery refers to operative resection of persistent or recurrent disease in patients initially treated with intention-to-cure nonoperative management. In non-small-cell lung cancer, salvage surgery may be effective in treating selected patients with locally progressive tumors, recurrent local or locoregional disease, or local complications after nonoperative therapy. Importantly, those patients who may be candidates for salvage surgery are evolving, in terms of disease stage as well as the types of attempted definitive therapy received.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-328Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg. 1995;60(3):615-623.
Beckles MA, Spiro SG, Colice GL, Rudd RM. The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest. 2003;123(1):105S-114S.
Berry MF, Hanna J, Tong BC, et al. Risk factors for morbidity after lobectomy for lung cancer in elderly patients. Ann Thorac Surg. 2009;88(4):1093-1099.
Leduc C, Antoni D, Charloux A, Falcoz P-E, Quoix E. Comorbidities in the management of patients with lung cancer. Eur Respir J. 2017;49(3):1601721. doi:10.1183/13993003.01721-2016
Casiraghi M, Maisonneuve P, Piperno G, et al. Salvage surgery after definitive chemoradiotherapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2017;29(2):233-241. doi:10.1053/j.semtcvs.2017.02.001
Al-Sahaf M, Lim E. The association between surgical volume, survival and quality of care. J Thorac Dis. 2015;7(suppl 2):152-155. doi:10.3978/j.issn.2072-1439.2015.04.08
Antonoff MB, Sofocleous CT, Callstrom MR, Nguyen Q-N. The roles of surgery, stereotactic radiation, and ablation for treatment of pulmonary metastases. J Thorac Cardiovasc Surg. 2022;163(2):495-502. doi:10.1016/j.jtcvs.2021.01.143
Hamada A, Soh J, Mitsudomi T. Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(1):555-562. doi:10.21037/tlcr-20-453
Allibhai Z, Cho BCJ, Taremi M, et al. Surgical salvage following stereotactic body radiotherapy for early-stage NSCLC. Eur Respir J. 2012;39(4):1039-1042.
Bauman JE, Mulligan MS, Martins RG, Kurland BF, Eaton KD, Wood DE. Salvage lung resection after definitive radiation (>59 Gy) for non-small cell lung cancer: surgical and oncologic outcomes. Ann Thorac Surg. 2008;86(5):1632-1639. doi:10.1016/j.athoracsur.2008.07.042
Bral S, Gevaert T, Linthout N, et al. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a phase II trial. Int J Radiat Oncol Biol Phys. 2011;80(5):1343-1349.
Lee JM, Jin GY, Goldberg SN, et al. Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report. Radiology. 2004;230(1):125-134. doi:10.1148/radiol.2301020934
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in lung cancer: current landscape and future directions. Front Immunol. 2022;13:823618. doi:10.3389/fimmu.2022.823618
Romero-Vielva L, Viteri S, Moya-Horno I, et al. Salvage surgery after definitive chemo-radiotherapy for patients with non-small cell lung cancer. Lung Cancer. 2019;133:117-122. doi:10.1016/j.lungcan.2019.05.010
Antonoff MB, Correa AM, Sepesi B, et al. Salvage pulmonary resection after stereotactic body radiotherapy: a feasible and safe option for local failure in selected patients. J Thorac Cardiovasc Surg. 2017;154(2):689-699. doi:10.1016/j.jtcvs.2017.03.142
Brooks ED, Verma V, Senan S, et al. Salvage therapy for locoregional recurrence after stereotactic ablative radiotherapy for early-stage NSCLC. J Thorac Oncol. 2020;15(2):176-189. doi:10.1016/j.jtho.2019.10.016
Roesch J, Andratschke N, Guckenberger M. SBRT in operable early stage lung cancer patients. Transl Lung Cancer Res. 2014;3(4):212-224.
Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25(8):947-952.
Vansteenkiste J, De Ruysscher D, Eberhardt WEE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi89-vi98.
Kumar SS, McGarry RC. Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy. Transl Lung Cancer Res. 2019;8(suppl 2):S213-S221. doi:10.21037/tlcr.2019.09.06
Nakamura M, Nishikawa R, Mayahara H, et al. Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer. J Thorac Dis. 2019;11(1):214-221.
Mitchell KG, Nelson DB, Corsini EM, et al. Surveillance after treatment of non-small-cell lung cancer: a call for multidisciplinary standardization. Innovations. 2020;15(1):57-65. doi:10.1177/1556984519886281
Lababede O, Meziane MA. The eighth edition of TNM staging of lung cancer: reference chart and diagrams. Oncologist. 2018;23(7):844-848. doi:10.1634/theoncologist.2017-0659
Network NCC. Non-small cell lung cancer (Version 5.2022). Accessed September 27, 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39-51. doi:10.1016/j.jtho.2015.09.009
Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):7S-37S. doi:10.1378/chest.12-2377
Curran WJ, Jr., Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/jnci/djr325
Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1-iv21. doi:10.1093/annonc/mdx222
Subotic D, Van Schil P, Grigoriu B. Optimising treatment for post-operative lung cancer recurrence. Eur Respir J. 2016;47(2):374-378. doi:10.1183/13993003.01490-2015
Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, DeCamp MM. Varying recurrence rates and risk factors associated with different definitions of local recurrence in patients with surgically resected, stage I nonsmall cell lung cancer. Cancer. 2010;116(10):2390-2400. doi:10.1002/cncr.25047
Howlader N, Noone A-M, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. National Cancer Institute; 2014.
Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677-682.
Hoyer M, Roed H, Hansen AT, et al. Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(4):S128-S135.
Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93(5):989-996.
Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer. 2010;68(1):72-77.
Sun B, Brooks ED, Komaki RU, et al. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: results of a phase 2 clinical trial. Cancer. 2017;123(16):3031-3039.
Timmerman R, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070-1076.
Timmerman RD, Hu C, Michalski JM, et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer. JAMA Oncol. 2018;4(9):1287-1288. doi:10.1001/jamaoncol.2018.1258
Timmerman RD, Fernando HC. A Radiation Oncologist's and Thoracic Surgeon's View on the Role of Stereotactic Ablative Radiotherapy for Operable Lung Cancer. Elsevier; 2013:8-13.
Tandberg DJ, Tong BC, Ackerson BG, Kelsey CR. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. Cancer. 2018;124(4):667-678. doi:10.1002/cncr.31196
Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27(20):3290-3296. doi:10.1200/jco.2008.21.5681
Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol. 2014;9(6):834-842. doi:10.1097/jto.0000000000000185
Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7):S94-S100. doi:10.1097/JTO.0b013e318074de34
Wink KCJ, van Baardwijk A, Troost EGC, De Ruysscher D. Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: incidence and proposed risk factors. Cancer Treat Rev. 2017;56:8-15.
Baère T, Palussière J, Aupérin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240(2):587-596. doi:10.1148/radiol.2402050807
Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H. Percutaneous radiofrequency ablation of malignancies in the lung. Am J Roentgenol. 2000;174(1):57-59. doi:10.2214/ajr.174.1.1740057
Fernando HC, Hoyos AD, Landreneau RJ, et al. Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. J Thorac Cardiovasc Surg. 2005;129(3):639-644. doi:10.1016/j.jtcvs.2004.10.019
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929.
Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301-1311. doi:10.1200/jco.21.01308
Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;158(1):269-276.
Van Breussegem A, Hendriks JM, Lauwers P, Van Schil PE. Salvage surgery after high-dose radiotherapy. J Thorac Dis. 2017;9(suppl 3):S193-S200. doi:10.21037/jtd.2017.03.88
Dickhoff C, Rodriguez Schaap PM, Otten RHJ, Heymans MW, Heineman DJ, Dahele M. Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review. Ther Adv Med Oncol. 2018;10:175883591878798. doi:10.1177/1758835918787989
Sonobe M, Yutaka Y, Nakajima D, et al. Salvage surgery after chemotherapy or chemoradiotherapy for initially unresectable lung carcinoma. Ann Thorac Surg. 2019;108(6):1664-1670. doi:10.1016/j.athoracsur.2019.06.087
Paul S, Altorki NK, Sheng S, et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg. 2010;139(2):366-378.
Ceppa DP, Kosinski AS, Berry MF, et al. Thoracoscopic lobectomy has increasing benefit in patients with poor pulmonary function: a Society of Thoracic Surgeons Database analysis. Ann Surg. 2012;256(3):487-493. doi:10.1097/SLA.0b013e318265819c
Medbery RL, Gillespie TW, Liu Y, et al. Nodal upstaging is more common with thoracotomy than with VATS during lobectomy for early-stage lung cancer: an analysis from the National Cancer Data Base. J Thorac Oncol. 2016;11(2):222-233.
Yang C-FJ, Kumar A, Klapper JA, et al. A national analysis of long-term survival following thoracoscopic versus open lobectomy for stage I non-small-cell lung cancer. Ann Surg. 2019;269(1):163-171.
Van Haren RM, Mehran RJ, Mena GE, et al. Enhanced recovery decreases pulmonary and cardiac complications after thoracotomy for lung cancer. Ann Thorac Surg. 2018;106(1):272-279. doi:10.1016/j.athoracsur.2018.01.088
Kohman LJ, Gu L, Altorki N, et al. Biopsy first: lessons learned from cancer and leukemia group B (CALGB) 140503. J Thorac Cardiovasc Surg. 2017;153(6):1592-1597.
Martin JT, Durbin EB, Chen L, et al. Nodal upstaging during lung cancer resection is associated with surgical approach. Ann Thorac Surg. 2016;101(1):238-245.
Whitson BA, Groth SS, Duval SJ, Swanson SJ, Maddaus MA. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg. 2008;86(6):2008-2018.
Villamizar N, Swanson SJ. Lobectomy vs. segmentectomy for NSCLC (T<2 cm). Ann Cardiothorac Surg. 2014;3(2):160-166.
Suzuki K, Saji H, Aokage K, et al. Comparison of pulmonary segmentectomy and lobectomy: safety results of a randomized trial. J Thorac Cardiovasc Surg. 2019;158(3):895-907. doi:10.1016/j.jtcvs.2019.03.090
Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607-1617. doi:10.1016/s0140-6736(21)02333-3
Altorki NK, Wang X, Wigle D, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Resp Med. 2018;6(12):915-924. doi:10.1016/s2213-2600(18)30411-9
Shimada Y, Suzuki K, Okada M, et al. Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for stage III non-small-cell lung cancer. Interact Cardiovasc Thorac Surg. 2016;23(6):895-901. doi:10.1093/icvts/ivw245
Dickhoff C, Dahele M, Paul MA, et al. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer. Lung Cancer. 2016;94:108-113. doi:10.1016/j.lungcan.2016.02.005
Suzuki S, Asakura K, Okui M, et al. Safety and efficacy of salvage surgery for non-small cell lung cancer: a retrospective study of 46 patients from four keio-affiliated hospitals. Gen Thorac Cardiovasc Surg. 2022;70(10):891-899. doi:10.1007/s11748-022-01808-4
Chen F, Matsuo Y, Yoshizawa A, et al. Salvage lung resection for non-small cell lung cancer after stereotactic body radiotherapy in initially operable patients. J Thorac Oncol. 2010;5(12):1999-2002.
Neri S, Takahashi Y, Terashi T, et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. J Thorac Oncol. 2010;5(12):2003-2007.
Shimizu K, Ohtaki Y, Suzuki K, et al. Salvage surgery for non-small cell lung cancer after definitive radiotherapy. Ann Thorac Surg. 2021;112(3):862-873.
Mitchell KG, Farooqi A, Ludmir EB, et al. Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. J Thorac Cardiovasc Surg. 2021;161(4):1497-1504. doi:10.1016/j.jtcvs.2020.02.134
Gomez DR, Blumenschein GR, Jr., Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672-1682. doi:10.1016/s1470-2045(16)30532-0
Mitchell KG, Farooqi A, Ludmir EB, et al. Improved overall survival with comprehensive local consolidative therapy in synchronous oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2020;21(1):37-46. doi:10.1016/j.cllc.2019.07.007
Altan M, Sui D, Gandhi S, et al. Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study. Amer Soc Clin Oncol. 2022;40:9049.
Elamin YY, Antonoff M, Blakely C, et al. Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR). Ann Oncol. 2018;29:viii547.
Elamin Y, Gandhi S, Antonoff M, et al. BRIGHTSTAR: a pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC. J Clin Oncol. 2020;38(15_suppl):9624. doi:10.1200/JCO.2020.38.15_suppl.9624
Antonoff MB. Surgical resection after targeted therapy in stage IV NSCLC: nuances and considerations. presented at: North American Conference on Lung Cancer; 2022; Chicago, IL.